Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, ...

The first 12 months on the market for Apellis’ geographic atrophy (GA) drug Syfovre have been a roller-coaster ride. And there’s still more loops to negotiate. On Tuesday, when Apellis presented its ...

Apellis’ geographic atrophy (GA) drug Syfovre delivered what CEO Cedric Francois called “robust” growth in the first quarter, as its sales topped analysts’ expectations. But investors still dragged ...

Apellis Pharmaceuticals, Inc. announced that the Therapeutic Goods Administration (TGA) in Australia has approved its treatment SYFOVRE® (pegcetacoplan) for adult patients suffering from geographic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Apellis is exclusively distributing injection kits with ...

Apellis Pharmaceuticals reported strong financial results for the full year 2024, with total revenues reaching $781.4 million, a 97% increase from the previous year, primarily driven by SYFOVRE® ...

Citi said it believes the sell-off in Apellis Pharmaceuticals (NASDAQ:APLS) shares following the company’s Q1 earnings report is “overdone.” The investment bank said Q1 sales of Apellis’s drug Syfovre ...

The company generated Syfovre sales of $167.8 million and $611.9 million for the fourth quarter and full year 2024, respectively. Delivered approximately 94,000 Syfovre doses to physician practices in ...

More than 100,000 vials have been distributed/administered between real world and clinical trials; since last update, confirmed one additional event of retinal ...

Credit: Apellis. Syfovre is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis announced that as part of its investigation into real-world safety ...